{
    "nct_id": "NCT03045406",
    "official_title": "Apixaban for the Treatment of Venous Thromboembolism in Patients With Cancer: A Prospective Randomized Open Blinded End-Point (Probe) Study",
    "inclusion_criteria": "* Consecutive patients with a newly diagnosed, objectively confirmed: symptomatic or unsuspected, proximal lower-limb DVT or symptomatic PE or unsuspected PE in a segmental or more proximal pulmonary artery;\n* Any type of cancer (other than basal-cell or squamous-cell carcinoma of the skin, primary brain tumor or intracerebral metastasis and acute leukemia);\n* Signed and dated informed consent of the patient, available before the start of any specific trial procedure.\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "* age <18 years;\n* ECOG Performance Status III or IV;\n* life expectancy of less than 6 months;\n\nRelated to anticoagulant treatment:\n\n* administration of therapeutic doses of LMWH, fondaparinux, or unfractionated heparin (UFH) for more than 72 hours before randomization;\n* 3 or more doses of a vitamin K antagonist before randomization;\n* thrombectomy, vena cava filter insertion, or thrombolysis used to manage the index episode;\n* indication for anticoagulant treatment for a disease other than the index VTE episode;\n\nRelated to bleeding risk:\n\n* thienopyridine therapy (clopidogrel, prasugrel, or ticagrelor) or aspirin over 165 mg daily or dual antiplatelet therapy;\n* active bleeding or a high risk of bleeding contraindicating anticoagulant treatment;\n* recent (in the last 1 month prior to randomization) brain, spinal or ophthalmic surgery\n* hemoglobin level lower than 8 g/dL (5.0 mmol/L) or platelet count <75x10^9/L or history of heparin induced thrombocytopenia;\n* creatinine clearance < 30 ml /min based on the Cockcroft Gault equation;\n* acute hepatitis, chronic active hepatitis, liver cirrhosis; or an alanine aminotransferase level 3 times or more and/or bilirubin level 2 times or more higher the upper limit of the normal range;\n* uncontrolled hypertension (systolic BP> 180 mmHg or diastolic BP > 100 mmHg despite antihypertensive treatment);\n* concomitant use of strong inhibitors or inducers of both cytochrome P-450 3A4 and P-Glycoprotein;\n\nStandard criteria:\n\n* bacterial endocarditis;\n* hypersensitivity to the active substance or to any of the excipients of study drug;\n* patients participation in other pharmaco therapeutic program with an experimental therapy that is known to effect the coagulation system;\n* childbearing potential without proper contraceptive measures, pregnancy, or breast feeding;\n* any condition that as judged by the Investigator would place the subject at increased risk of harm if he/she participated in the study.",
    "miscellaneous_criteria": ""
}